ınterleukin ınhibitors治疗银屑病患者PASI90反应的预测因素：观察性队列研究

IF 3.6 4区医学 Q2 DERMATOLOGY

Anais brasileiros de dermatologia Pub Date : 2025-06-18 DOI:10.1016/j.abd.2025.501132

Burhan Engin , Yusuf Demir , Sera Nur Yucesoy , Tumay Ak

{"title":"ınterleukin ınhibitors治疗银屑病患者PASI90反应的预测因素：观察性队列研究","authors":"Burhan Engin , Yusuf Demir , Sera Nur Yucesoy , Tumay Ak","doi":"10.1016/j.abd.2025.501132","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Psoriasis is a chronic multisystem disorder, and the inhibition of different cytokine pathways has been associated with different treatment responses.</div></div><div><h3>Objective</h3><div>To demonstrate independent predictors of PASI90 response in patients with psoriasis under biologic therapy and compare the effectiveness of different biologic classes</div></div><div><h3>Methods</h3><div>This cross-sectional study was conducted in a single tertiary center between January 2023 and May 2024 and included 623 patients (M/F: 320/303). PASI90 response was the primary end-point of the study, and PASI100 was the secondary end-point. Univariate and multivariate cox-regression analyses were used to identify predictors of PASI90. The efficacy of different biologic classes for achieving PASI90 and PASI100 responses was assessed using the Kaplan–Meier method.</div></div><div><h3>Results</h3><div>The age of disease onset (HR = 1.037, 95% CI [1.029‒1.044], p < 0.001) and being biologic-naïve (HR = 1.261, 95% CI [1.046‒1.521], p = 0.015) were identified as significant predictors of PASI90 response. IL23 inhibitors showed considerably superior efficacy in achieving PASI90 response than both TNF inhibitors (p = 0.042) and ustekinumab (p = 0.027). Also, IL17 inhibitors exhibited near-significantly higher effectiveness than TNF inhibitors (p = 0.090) and ustekinumab (p = 0.050). The performance of biologic classes was not substantially different in reaching PASI100 overall.</div></div><div><h3>Study limitations</h3><div>The most important limitation of this study is the retrospective data collection.</div></div><div><h3>Conclusion</h3><div>Age of disease onset and being biologically naïve were positively associated with achieving PASI90 response, whereas ustekinumab use was negatively associated. Age of disease onset was the strongest predictor of PASI90. Also, IL23 and IL17 inhibition, especially IL23, appeared to provide a better therapeutic response.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 4","pages":"Article 501132"},"PeriodicalIF":3.6000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Predictors of PASI90 response in patients with psoriasis treated with ınterleukin ınhibitors: observational cohort study\",\"authors\":\"Burhan Engin , Yusuf Demir , Sera Nur Yucesoy , Tumay Ak\",\"doi\":\"10.1016/j.abd.2025.501132\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Psoriasis is a chronic multisystem disorder, and the inhibition of different cytokine pathways has been associated with different treatment responses.</div></div><div><h3>Objective</h3><div>To demonstrate independent predictors of PASI90 response in patients with psoriasis under biologic therapy and compare the effectiveness of different biologic classes</div></div><div><h3>Methods</h3><div>This cross-sectional study was conducted in a single tertiary center between January 2023 and May 2024 and included 623 patients (M/F: 320/303). PASI90 response was the primary end-point of the study, and PASI100 was the secondary end-point. Univariate and multivariate cox-regression analyses were used to identify predictors of PASI90. The efficacy of different biologic classes for achieving PASI90 and PASI100 responses was assessed using the Kaplan–Meier method.</div></div><div><h3>Results</h3><div>The age of disease onset (HR = 1.037, 95% CI [1.029‒1.044], p < 0.001) and being biologic-naïve (HR = 1.261, 95% CI [1.046‒1.521], p = 0.015) were identified as significant predictors of PASI90 response. IL23 inhibitors showed considerably superior efficacy in achieving PASI90 response than both TNF inhibitors (p = 0.042) and ustekinumab (p = 0.027). Also, IL17 inhibitors exhibited near-significantly higher effectiveness than TNF inhibitors (p = 0.090) and ustekinumab (p = 0.050). The performance of biologic classes was not substantially different in reaching PASI100 overall.</div></div><div><h3>Study limitations</h3><div>The most important limitation of this study is the retrospective data collection.</div></div><div><h3>Conclusion</h3><div>Age of disease onset and being biologically naïve were positively associated with achieving PASI90 response, whereas ustekinumab use was negatively associated. Age of disease onset was the strongest predictor of PASI90. Also, IL23 and IL17 inhibition, especially IL23, appeared to provide a better therapeutic response.</div></div>\",\"PeriodicalId\":7787,\"journal\":{\"name\":\"Anais brasileiros de dermatologia\",\"volume\":\"100 4\",\"pages\":\"Article 501132\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anais brasileiros de dermatologia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0365059625000741\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anais brasileiros de dermatologia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0365059625000741","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景银屑病是一种慢性多系统疾病，不同细胞因子通路的抑制与不同的治疗反应有关。目的探讨银屑病生物治疗患者PASI90反应的独立预测因素，并比较不同生物治疗类别的有效性。方法：本横断面研究于2023年1月至2024年5月在单一三级中心进行，纳入623例患者（M/F: 320/303）。PASI90缓解是研究的主要终点，PASI100是次要终点。采用单因素和多因素cox-回归分析确定PASI90的预测因素。使用Kaplan-Meier方法评估不同生物类别对达到PASI90和PASI100反应的疗效。ResultsThe疾病的发病年龄(HR = 1.037,95%可信区间(1.029 - -1.044),p & lt; 0.001)和biologic-naive (HR = 1.261,95%可信区间(1.046 - -1.521),0.015 p = )被确定为PASI90响应的重要预测因子。在实现PASI90应答方面，il - 23抑制剂的疗效明显优于TNF抑制剂（p = 0.042）和ustekinumab （p = 0.027）。此外，IL17抑制剂比TNF抑制剂（p = 0.090）和ustekinumab （p = 0.050）表现出几乎显著更高的有效性。在达到总分100分方面，生物课的表现没有实质性差异。研究局限性本研究最重要的局限性是回顾性数据收集。结论：发病年龄和生物学naïve与PASI90应答呈正相关，而ustekinumab的使用与PASI90应答呈负相关。发病年龄是PASI90的最强预测因子。此外，抑制il - 23和il - 17，尤其是il - 23，似乎提供了更好的治疗反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Predictors of PASI90 response in patients with psoriasis treated with ınterleukin ınhibitors: observational cohort study

Background

Psoriasis is a chronic multisystem disorder, and the inhibition of different cytokine pathways has been associated with different treatment responses.

Objective

To demonstrate independent predictors of PASI90 response in patients with psoriasis under biologic therapy and compare the effectiveness of different biologic classes

Methods

This cross-sectional study was conducted in a single tertiary center between January 2023 and May 2024 and included 623 patients (M/F: 320/303). PASI90 response was the primary end-point of the study, and PASI100 was the secondary end-point. Univariate and multivariate cox-regression analyses were used to identify predictors of PASI90. The efficacy of different biologic classes for achieving PASI90 and PASI100 responses was assessed using the Kaplan–Meier method.

Results

The age of disease onset (HR = 1.037, 95% CI [1.029‒1.044], p < 0.001) and being biologic-naïve (HR = 1.261, 95% CI [1.046‒1.521], p = 0.015) were identified as significant predictors of PASI90 response. IL23 inhibitors showed considerably superior efficacy in achieving PASI90 response than both TNF inhibitors (p = 0.042) and ustekinumab (p = 0.027). Also, IL17 inhibitors exhibited near-significantly higher effectiveness than TNF inhibitors (p = 0.090) and ustekinumab (p = 0.050). The performance of biologic classes was not substantially different in reaching PASI100 overall.

Study limitations

The most important limitation of this study is the retrospective data collection.

Conclusion

Age of disease onset and being biologically naïve were positively associated with achieving PASI90 response, whereas ustekinumab use was negatively associated. Age of disease onset was the strongest predictor of PASI90. Also, IL23 and IL17 inhibition, especially IL23, appeared to provide a better therapeutic response.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Anais brasileiros de dermatologia DERMATOLOGY-

CiteScore

2.40

自引率

0.00%

发文量

184

审稿时长

32 days

期刊介绍： The journal is published bimonthly and is devoted to the dissemination of original, unpublished technical-scientific study, resulting from research or reviews of dermatological topics and related matters. Exchanges with other publications may be accepted.